Novel aspects of Sjögren’s syndrome in 2012

BMC Medicine

Yehuda Shoenfeld²  Paola Toniati⁸  Francesco Semeraro⁶  Amerigo Santoro¹  Giuseppe Nascimbeni⁶  Andrea Lojacono⁷  Franco Franceschini⁸  Maria-Giulia Fenini⁵  Marta Favero³  Andrea Doria³  Ilaria Cavazzana⁸  Laura Andreoli⁴  Angela Tincani⁴ 

[1] Pathology Unit, Spedali Civili, Piazzale Spedali Civili 1, Brescia, 25100, Italy;Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Hashomer, 52621, Israel;Rheumatology Unit, Department of Medicine, University of Padua, Azienda Ospedaliera di Padova, Via Giustiniani 2, Padua, 35128, Italy;Chair of Rheumatology, Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy;Rheumatology Unit, Vallecamonica Hospital, Via Manzoni 142, Esine (Brescia), 25040, Italy;Ophthalmology Unit, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, Brescia, 25100, Italy;Obstetrics and Gynecology Unit, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, Brescia, 25100, Italy;Rheumatology and Clinical Immunology Unit, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia, Italy

关键词: Vitamin D;    Sjögren’s syndrome;    Sicca syndrome;    Peripheral neuropathy;    Lymphoma;    Dry eye syndrome;    Chronic sialoadenitis;    Autoimmune diseases;    Autoantibodies;    Anti-B cell therapies;   

Others  :  857113
DOI  :  10.1186/1741-7015-11-93

 received in 2012-11-19, accepted in 2013-02-15,  发布年份 2013

【 摘 要 】

Sjögren’s syndrome (SS) is a systemic progressive autoimmune disease characterized by a complex pathogenesis requiring a predisposing genetic background and involving immune cell activation and autoantibody production. The immune response is directed to the exocrine glands, causing the typical ‘sicca syndrome’, but major organ involvement is also often seen. The etiology of the disease is unknown. Infections could play a pivotal role: compared to normal subjects, patients with SS displayed higher titers of anti-Epstein-Barr virus (EBV) early antigens, but lower titers of other infectious agent antibodies such as rubella and cytomegalovirus (CMV) suggest that some infections may have a protective role against the development of autoimmune disease. Recent findings seem to show that low vitamin D levels in patients with SS could be associated with severe complications such as lymphoma and peripheral neuropathy. This could open new insights into the disease etiology. The current treatments for SS range from symptomatic therapies to systemic immunosuppressive drugs, especially B cell-targeted drugs in cases of organ involvement. Vitamin D supplementation may be an additional tool for optimization of SS treatment.

【 授权许可】

   
2013 Tincani et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y: Sjögren’s syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012, 26:105-117.
• [2]Mavragani CP, Moutsopoulos HM: The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010, 9:A305-A310.
• [3]Ice JA, Li H, Adrianto I, Lin PC, Kelly JA, Montgomery CG, Lessard CJ, Moser KL: Genetics of Sjögren’s syndrome in the genome-wide association era. J Autoimmun 2012, 39:57-63.
• [4]Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM: HLA and Sjögren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012, 11:281-287.
• [5]Roitberg-Tambur A, Friedmann A, Safirman C, Markitziu A, Ben-Chetrit E, Rubinow A, Moutsopoulos HM, Stavropoulos E, Skopouli FN, Margalit H: Molecular analysis of HLA class II genes in primary Sjögren’s syndrome. A study of Israeli Jewish and Greek non-Jewish patients. Hum Immunol 1993, 36:235-242.
• [6]Piram M, Maldinia C, Mahr A: Effect on race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheum 2012, 24:193-200.
• [7]Ramos-Casals M, Brito-Zeròn P, Sisò-Almirall A, Bosch X: Primary Sjögren syndrome. BMJ 2012, 344:e3821.
• [8]Tzioufas AG, Moutsopoulos HM: Sjögren’s syndrome. In Rheumatology. 2nd edition. Edited by Klippel JH, Dieppe PA. Maryland Heights, MI: Mosby; 1999. 7.32.1-11
• [9]Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s syndrome: Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
• [10]Baldini C, Talarico R, Tzioufas AG, Bombardieri S: Classification criteria for Sjögren’s syndrome: a critical review. J Autoimmun 2012, 39:9-14.
• [11]Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, Saraux A, Devauchelle-Pensec V: Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: a systematic review. Autoimmun Rev 2013, 12:416-420.
• [12]Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T: American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012, 64:475-487.
• [13]Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, Hamann S, Larkin G, McNamara NA, Greenspan JS, Daniels TE: Sjögren’s International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol 2010, 149:405-415.
• [14]Tzioufas AG, Moutsopoulos HM: Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren’s syndrome. Nat Clin Pract Rheumatol 2008, 4:454-455.
• [15]Salaffi F, Carotti M, Iagnocco A, Luccioli F, Ramonda R, Sabatini E, De Nicola M, Maggi M, Priori R, Valesini G, Gerli R, Punzi L, Giuseppetti GM, Salvolini U, Grassi W: Ultrasonography of salivary glands in primary Sjögren’s syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford) 2008, 47:1244-1249.
• [16]Milic V, Petrovic R, Boricic I, Radunovic G, Marinkovic-Eric J, Jeremic P, Damjanov N: Ultrasonography of major salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria for primary Sjögren’s syndrome. Rheumatology 2012, 51:1081-1085.
• [17]Thoft RA, Friend J: The X, Y, Z hypothesis of corneal epithelial maintenance. Invest Ophthalmol Vis Sci 1983, 24:1442.
• [18]Lemp MA: Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J 1995, 21:221-232.
• [19]Dry Eye Workshop: The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007, 5:75-92.
• [20]Stern ME, Pflugfelder SC: Inflammation in dry eye. Ocul Surf 2004, 2:124-130.
• [21]Garcia-Carrasco M, Ramos-Casals R, Rosas J, Pallares L, Calvo-Alen J, Cervera R, Font J, Ingelmo M: Primary Sjögren’s syndrome. Clinical and immunological disease patterns in a cohort of 400 patients. Medicine 2002, 81:270-280.
• [22]Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM: Clinical evolution and morbidity and mortality of primary Sjögren’s syndrome. Seminar Arthritis Rheum 2000, 29:296-304.
• [23]ter Borg EJ, Risselada AP, Kelder JC: Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren’s syndrome: a retrospective analysis of 65 patients in the Netherlands. Seminar Arthritis Rheum 2011, 40:547-551.
• [24]Seror R, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Ramos-Casals M, Ravaud P, Theander E, Tzioufas A, Vitali C: Outcome measures for primary Sjögren’s syndrome. J Autoimmun 2012, 39:97-102.
• [25]Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L, and the GEMESS Study Group: Primary Sjögren’s syndrome in Spain. Clinical and immunological expression in 1010 patients. Medicine 2008, 87:210-219.
• [26]Manoussakis MN, Kapsogeorgou EK: The role of intrinsic epithelial activation in the pathogenesis of Sjögren’s syndrome. J Autoimmun 2010, 35:219-224.
• [27]Selmi C, Meroni PL, Gershwin ME: Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun 2012, 39:34-42.
• [28]Ng WF, Bowman SJ: Primary Sjögren’s syndrome: too dry and too tired. Rheumatology 2012, 49:844-853.
• [29]Hatron PY, Tillie-Leblond I, Launay D, Hachulla E, Fauchais AL, Wallaert B: Pulmonary manifestations of Sjögren’s syndrome. Presse Med 2011, 40:e49-e64.
• [30]Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I, Viola BF, Valzorio B, Mazzucchelli C, Cattaneo R, Scolari F, Maiorca R: Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial Transplant 2001, 16:2328-2336.
• [31]Kittridge A, Routhouska SB, Korman NJ: Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg 2011, 15:8-14.
• [32]Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, Lambert M, Launay D, Loustaud-Ratti V, Bezanahari H, Liozon E, Hachulla E, Jauberteau MO, Vidal E, Hatron PY: Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 2010, 49:1164-1172.
• [33]Ebert EC: Gastrointestinal and hepatic manifestations of Sjögren syndrome. J Clin Gastroenterol 2012, 46:25-30.
• [34]Mavragani CP, Fragoulis GE, Moutsopoulos HM: Endocrine alterations in primary Sjögren’s syndrome: an overview. J Autoimmun 2012, 39:354-358.
• [35]Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, Dalakas MC: Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012, 39:27-33.
• [36]Chai J, Logigian EL: Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol 2010, 23:509-513.
• [37]Singh N, Cohen PL: The T cell in Sjögren’s syndrome: force majeure, not spectateur. J Autoimmun 2012, 39:229-233.
• [38]Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A: B cells in Sjögren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 2012, 39:161-167.
• [39]Varin MM, Guerrier T, Devauchelle-Pensec V, Jamin C, Youinou P, Pers JO: In Sjögren’s syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012, 11:252-258.
• [40]Manoussakis MN, Boiu S, Korkolopoulou P, Kapsogeorgou EK, Kavantzas N, Ziakas P, Patsouris E, Moutsopoulos HM: Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
• [41]González S, Aguilera S, Urzúa U, Quest AF, Molina C, Alliende C, Hermoso M, González MJ: Mechanotransduction and epigenetic control in autoimmune diseases. Autoimmun Rev 2011, 10:175-179.
• [42]Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM: Pathogenesis of Sjögren’s syndrome: what we know and what we should learn. J Autoimmun 2012, 39:4-8.
• [43]Regezi JA, Sciubba JJ, Jordan RCK: Oral Pathology - Clinical pathological Correlations. 6th edition. New York, NY: Elsevier-Saunders; 2012.
• [44]Tzioufas AG, Voulgarelis M: Update on Sjögren’s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007, 21:989-1010.
• [45]Zandbelt MM, Vogelzangs J, Van De Putte LB, Van Venrooij WJ, Van Den Hoogen FH: Anti-alpha-fodrin antibodies do not add much to the diagnosis of Sjögren’s syndrome. Arthritis Res Ther 2004, 6:R33-R38.
• [46]Bournia VK, Vlachoyionnapoulos PG: Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012, 39:15-26.
• [47]Hernández-Molina G, Leal-Alegre G, Michel-Peregrina M: The meaning of anti-Ro and anti-La antibodies in primary Sjögren’s syndrome. Autoimmun Rev 2011, 10:123-125.
• [48]Barcellos KS, Nonogaki S, Enokihara MM, Teixeira MS, Andrade LE: Differential expression of Ro/SSA 60 kDa and La/SSB, but not Ro/SSA 52 kDa, mRNA and protein in minor salivary glands from patients with primary Sjögren’s syndrome. J Rheumatol 2007, 34:1283-1292.
• [49]Sisto M, Lisi S, Lofrumento D, D'Amore M, Scagliusi P, Mitolo V: Autoantibodies from Sjögren’s syndrome trigger apoptosis in salivary gland cell line. Ann N Y Acad Sci 2007, 1108:418-425.
• [50]Lisi S, Sisto M, Lofrumento DD, Cucci L, Frassanito MA, Mitolo V, D’Amore M: Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun 2010, 35:160-170.
• [51]Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibeni S, Puttini PS: Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
• [52]Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C: Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10:509-513.
• [53]Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F: Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011, 10:503-508.
• [54]Franceschini F, Cavazzana I: Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005, 38:55-63.
• [55]Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J: Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006, 35:312-321.
• [56]Cavazzana I, Franceschini F, Vassalini C, Danieli E, Quinzanini M, Airò P, Cattaneo R: Clinical and serological features of 35 patients with anti-Ki autoantibodies. Lupus 2005, 14:837-841.
• [57]Onouchi H, Muro Y, Tomita Y: Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. J Autoimmun 1999, 13:225-232.
• [58]Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, Franceschini F: Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 2008, 17:727-732.
• [59]Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A: Overlap connective tissue disease syndromes. Autoimmun Rev 2013, 12:363-373.
• [60]Lazarus MN, Isenberg DA: Development of additional autoimmune diseases in a population of patients with primary Sjögren’s syndrome. Ann Rheum Dis 2005, 64:1062-1064.
• [61]Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cárdenas-Roldán J, Pineda-Tamayo R, Guarin MR, Kleine LL, Rojas-Villarraga A, Anaya JM: Sjögren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun 2012, 39:199-205.
• [62]Yao Q, Altman RD, Wang X: Systemic lupus erythematosus with Sjögren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol 2012, 18:28-32.
• [63]Theander E, Jacobsson LTH: Features of systemic lupus erythematosus in patients with primary Sjögren’s syndrome. A cross-sectional analysis of the 11 items of the SLE criteria set and the levels of complement factors C3 and C4 in 100 primary Sjögren’s syndrome patients. Lupus 2005, 14:S231.
• [64]Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jauberteau MO, Hachulla E, Vidal E, Hatron PY: Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010, 9:595-599.
• [65]Carmona L, González-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R: Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003, 62:897-900.
• [66]Skoumal M, Wottawa A: Long-term observation study of Austrian patients with rheumatoid arthritis. Acta Med Austriaca 2002, 29:52-56.
• [67]Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI: Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:511-513.
• [68]Kauppi M, Pukkala E, Isomaki H: Elevated incidence of hematologic malignancies in patients with Sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997, 8:201-204.
• [69]Rodnan G: The natural history of progressive sclerosis (diffuse scleroderma). Bull Rheum Dis 1963, 1963:203-205.
• [70]Alarcón-Segovia D, Ibánez G, Hernández-Ortíz J, Velázquez-Forero F, González-Jiménez Y: Sjögren’s syndrome in progressive systemic sclerosis (scleroderma). Am J Med 1974, 57:78-85.
• [71]Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher-Lavenu MC, Sibilia J, Kahan A, Allanore Y: Systemic sclerosis-associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006, 54:2243-2249.
• [72]Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X: Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol 2007, 34:2253-2258.
• [73]Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, Gershwin ME: The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases–2008. Isr Med Assoc J 2008, 10:13-19.
• [74]Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y: Autoimmunity and environment: infections and autoimmunity - friends or foes? Trends Immunol 2009, 30:409-414.
• [75]Shapira Y, Agmon-Levin N, Selmi C, Petríková J, Barzilai O, Ram M, Bizzaro N, Valentini G, Matucci-Cerinic M, Anaya JM, Katz BS, Shoenfeld Y: Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun 2012, 39:112-116.
• [76]Sagi L, Baum S, Agmon-Levin N, Sherer Y, Katz BS, Barzilai O, Ram M, Bizzaro N, Sanmarco M, Trau H, Shoenfeld Y: Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011, 10:527-535.
• [77]Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, Shoenfeld Y: A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010, 34:55-58.
• [78]Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N, Ram M, Blank M, Tincani A, Rozman B, Cervera R, Shoenfeld Y: Common infectious agents prevalence in antiphospholipid syndrome. Lupus 2009, 18:1149-1153.
• [79]Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, Sherer Y, Anaya JM, Shoenfeld Y: Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci 2009, 1173:658-663.
• [80]Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y: Infectious serologies and autoantibodies in inflammatory bowel diseases. Insinuations at a true pathogenic role. Ann NY Acad Sci 2009, 1173:640-648.
• [81]Agmon-Levin N, Kivity S, Tzioufas AG, López Hoyos M, Rozman B, Efes I, Shapira Y, Shamis A, Amital H, Youinou P, Shoenfeld Y: Low levels of vitamin D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. J Autoimmun 2012, 39:234-239.
• [82]Kiraly SJ, Kiraly MA, Hawe RD, Makhani N: Vitamin D as a neuroactive substance: review. Scientific World J 2006, 6:125-139.
• [83]Chabas JF, Alluin O, Rao G, Garcia S, Lavaut MN, Risso JJ, Legre R, Magalon G, Khrestchatisky M, Marqueste T, Decherchi P, Feron F: Vitamin D2 potentiates axon regeneration. J Neurotrauma 2008, 25:1247-1256.
• [84]Turner MK, Hooten WM, Schmidt JE, Kerkvliet JL, Townsend CO, Bruce BK: Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. Pain Med 2008, 9:979-984.
• [85]Skalli S, Muller M, Pradines S, Halimi S, Wion-Barbot N: Vitamin D deficiency and peripheral diabetic neuropathy. Eur J Intern Med 2012, 23:e67-e68.
• [86]Valensi P, Le Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, LeFante C: A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications 2005, 19:247-253.
• [87]Lee P, Chen R: Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med 2008, 168:771-772.
• [88]Polesel J, Talamini R, Montella M, Parpinel M, Dal Maso L, Crispo A, Crovatto M, Spina M, La Vecchia C, Franceschi S: Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case–control study. Ann Oncol 2006, 17:713-718.
• [89]Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG: Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest 2009, 27:942-951.
• [90]Hickish T, Cunningham D, Colston K, Millar BC, Sandle J, Mackay AG, Soukop M, Sloane J: The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 1993, 68:668-672.
• [91]Andreoli L, Fredi M, Nalli C, Reggia R, Lojacono A, Motta M, Tincani A: Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 2012, 38:J197-J208.
• [92]Ambrosi A, Salomonsson S, Eliasson H, Zeffer E, Skog A, Dzikaite V, Bergman G, Fernlund E, Tingström J, Theander E, Rydberg A, Skogh T, Öhman A, Lundström U, Mellander M, Winqvist O, Fored M, Ekbom A, Alfredsson L, Källberg H, Olsson T, Gadler F, Jonzon A, Kockum I, Sonesson SE, Wahren-Herlenius M: Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis 2012, 71:334-340.
• [93]Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, Pisoni MP, Solerte L, Muscarà M, Lojacono A, Motta M, Cavazzana I, Ghirardello A, Vescovi F, Tombini V, Cimaz R, Gambari PF, Meroni PL, Canesi B, Tincani A: Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 2002, 11:716-721.
• [94]Marchesoni D, Mozzanega B, De Sandre P, Romagnolo C, Gambari PF, Maggino T: Gynaecological aspects of primary Sjögren’s syndrome. Eur J Obstet Gynecol Reprod Biol 1995, 63:49-53.
• [95]Haga HJ, Gjesdal CG, Irgens LM, Ostensen M: Reproduction and gynaecological manifestations in women with primary Sjögren’s syndrome: a case–control study. Scand J Rheumatol 2005, 34:45-48.
• [96]Tristano AG: The impact of rheumatic diseases on sexual function. Rheumatol Int 2009, 29:853-860.
• [97]Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, Falk SS, Liu Y, Szodoray P, Takakubo Y: Sex steroids in Sjögren’s syndrome. J Autoimmun 2012, 39:49-56.
• [98]Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG: Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol 2012, 8:399-411.
• [99]Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R: Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011, 7:CD008934.
• [100]Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ: Treatment of Sjögren’s syndrome-associated dry eye an evidence-based review. Ophthalmology 2011, 118:1242-1252.
• [101]Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A: The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011, 10:305-310.
• [102]Rihl M, Ulbricht K, Schmidt RE, Witte T: Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren’s syndrome. Rheumatology (Oxford) 2009, 48:796-799.
• [103]Yavuz S, Asfuroğlu E, Bicakcigil M, Toker E: Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren’s syndrome. Rheumatol Int 2011, 31:1045-1049.
• [104]Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM: Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005, 44:449-455.
• [105]Doria A, Arienti S, Rampudda M, Canova M, Tonon M, Sarzi-Puttini P: Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008, 7:192-197.
• [106]Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A: Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007, 6:190-195.
• [107]Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P: Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007, 6:529-536.
• [108]Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK: Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004.
• [109]Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ, American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines: Improvement in Sjögren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003, 49:394-398.
• [110]Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG: Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford) 2004, 43:1050-1053.
• [111]Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI): Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
• [112]Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H: Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
• [113]Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B: Successful treatment of a patient with primary Sjögren’s syndrome with rituximab. Clin Rheumatol 2006, 25:891-894.
• [114]Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X: Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis 2007, 66:351-357.
• [115]Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A: Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007, 57:310-317.
• [116]Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P: Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544.
• [117]Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM: Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008, 34:124-128.
• [118]Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O’Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
• [119]Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H: Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
• [120]Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, Hamidou M, Cantagrel A, Marcelli C, Rist S, Breban M, Launay D, Fain O, Gottenberg JE, Mariette X: Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012, 71:84-87.
• [121]Atzeni F, Doria A, Turiel M, Sarzi-Puttini P: What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun Rev 2007, 6:553-558.
• [122]Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA: Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren’s syndrome after B cell depletion therapy. Ann Rheum Dis 2012, 71:1881-1887.
• [123]Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006, 8:R129.